the functions and responsibilities of the NBA under the National Blood (Cth). Authority Act 2003 The Parties agree to establish the terms of reference for the Process Migration Governance Committee by Formal Notice agreed between them. The Process Migration Governance Committee will: comprise the chief executives of each Party (or any deputy nominated by each chief executive) and any other representatives nominated by each Party; meet on a basis agreed between the Parties. Starting Plasma and Plasma Material Provision of Starting Plasma CSL acknowledges that the Starting Plasma provided to it for the purposes of this Deed is funded by Australian Governments through the National Blood Arrangements. The Parties acknowledge that: CSL has informed the NBA that the size and technology of CSL’s Broadmeadows plasma fractionation facility means that ability to CSL’s achieve economies of scale and to provide internationally competitive pricing for Australian plasma products is facilitated through a throughput of plasma for fractionation in the order of 500 tonnes per year; at the Commencement Date, Australia is the primary customer of CSL’s Broadmeadows facility, while overseas customers also contribute to annual throughput; and [Not disclosed this clause provides for the availability of a minimum volume – of Starting Plasma for each financial year of the Agreement.] Despite clause 13.2, the NBA does not warrant or guarantee the quality, fitness for purpose or suitability of the Starting Plasma, or the quantity of Starting Plasma to be provided to CSL at any time or over any period. The NBA acknowledges that CSL relies on the Starting Plasma Provider holding a current TGA licence for blood collection, and having conducted such tests and procedures in relation to the Starting Plasma as are required to have been undertaken by that provider to meet TGA requirements, prior to delivery to CSL (subject to any requirements of CSL applying under the TG Act in relation to Starting Plasma). CSL and the NBA may agree by Formal Notice on a specification to apply for Starting Plasma suitable for particular Products under this Deed. obligations to produce and supply Products under this Deed are subject to: CSL’s circumstances affecting the timely provision of adequate Starting Plasma, which is available for production, to CSL; and circumstances in relation to safety concerns, latent defects, contaminants or donor issues which prevent or limit the effective use of Starting Plasma; in accordance with clause 43, where these circumstances are beyond the reasonable control of CSL, and are not able to be reasonably mitigated by CSL.
the functions and responsibilities of the NBA under the National Blood Authority Act 2003 (Cth). The Parties agree to establish the terms of reference for the Process Migration Governance Committee by Formal Notice agreed between them. The Process Migration Governance Committee will: comprise the chief executives of each Party (or any deputy nominated by each chief executive) and any other representatives nominated by each Party; meet on a basis agreed between the Parties. Starting Plasma and Plasma Material Provision of Starting Plasma CSL acknowledges that the Starting Plasma provided to it for the purposes of this Deed is funded by Australian Governments through the National Blood Arrangements. The Parties acknowledge that: CSL has informed the NBA that the size and technology of CSL’s Broadmeadows plasma fractionation facility means that CSL’s ability to achieve economies of scale and to provide internationally competitive pricing for Australian plasma products is facilitated through a throughput of plasma for fractionation in the order of 500 tonnes per year; at the Commencement Date, Australia is the primary customer of CSL’s Broadmeadows facility, while overseas customers also contribute to annual throughput; and [Not disclosed – this clause provides for the availability of a minimum volume of Starting Plasma for each financial year of the Agreement.] Despite clause 13.2, the NBA does not warrant or guarantee the quality, fitness for purpose or suitability of the Starting Plasma, or the quantity of Starting Plasma to be provided to CSL at any time or over any period. The NBA acknowledges that CSL relies on the Starting Plasma Provider holding a current TGA licence for blood collection, and having conducted such tests and procedures in relation to the Starting Plasma as are required to have been undertaken by that provider to meet TGA requirements, prior to delivery to CSL (subject to any requirements of CSL applying under the TG Act in relation to Starting Plasma). CSL and the NBA may agree by Formal Notice on a specification to apply for Starting Plasma suitable for particular Products under this Deed. CSL’s obligations to produce and supply Products under this Deed are subject to: circumstances affecting the timely provision of adequate Starting Plasma, which is available for production, to CSL; and circumstances in relation to safety concerns, latent defects, contaminants or donor issues which prevent or limit the effective use of Starting Plasma; in accordance with clause 43, where these circumstances are beyond the reasonable control of CSL, and are not able to be reasonably mitigated by CSL.
Final-NaFAA-for-Website.docx